The AHA, joined by the Association of American Medical Colleges and America's Essential Hospitals, today urged a federal appeals court to expedite their appeal of a lower court’s December dismissal of the groups’ lawsuit that sought to prevent Medicare payment cuts for many hospitals in the 340B Drug Pricing Program. Today’s request asked that the United States Court of Appeals for the District of Columbia Circuit establish an expedited schedule that would ensure completion of all briefing in the appeal by no later than the beginning of April and set a date for oral argument as soon as practicable upon completion of the briefing. The request to expedite briefing is joined by the hospitals that were part of the original lawsuit challenging the payment reduction – Eastern Maine Healthcare Systems in Brewer, ME, Henry Ford Health System in Detroit and Adventist Health System's Park Ridge Health in Hendersonville, NC. The lower court on Dec. 29 dismissed the lawsuit as premature, but it did not rule on the merits of the groups’ claim. The groups on Jan. 9 formally notified the court of their appeal.
 

Related News Articles

Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the state’s 340B contract pharmacy law…
Chairperson's File
Public
Advocacy is a core part of the work of the AHA, protecting and sustaining what hospitals and health systems need to truly care for our communities. We often…
Headline
A U.S. District Court for the District of Columbia judge June 27 ruled against Johnson & Johnson and sided with the Department of Health and Human Services…
Headline
The AHA June 16 released a report showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater…